Search

Objective: To study the effects of goserelin combined with endocrine drugs on disease progression and survival of premenopausal advanced breast cancer patients. Methods: We retrospectively analyzed the data of 157 cases of premenopausal advanced breast cancer patients in our hospital. Among them, 78 patients had goserelin during hospitalization were taken as control group, and another 79 patients taking goserelin and endocrine drugs in combination regimens as treatment group. Compare the disease progression during hospitalization and survival situation between two groups. Results: There were no differences in data during the course of standard treatment between groups (P>0.05). After treatment, the breast cancer disease progression were significantly better in the treatment group than in the control group, and differences between different time groups had statistical significance (P<0.05). In the one-year follow up, there were differences in the reoccurrence, cases with life quality classified as excellent and death cases between the two groups (P <0. 01). Conclusion: The combination of goserelin and endocrine drugs has good progression control effect for patients with advanced breast cancer before menopause. [ABSTRACT FROM AUTHOR]